Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | IL6 | P05231 | 1/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.68 |
| ▸ | GLUL | P15104 | 1/20 | 0.68 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisone SCHEMBL3408330 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL15304738 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL8262569 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL13620924 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL13323411 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL23974933 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL20459224 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL21281533 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL21883168 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A | |
| Prednisone SCHEMBL5572169 | 1.00 | HSD17B10 (1.00) | HSD17B10NR3C1HIF1ALMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200199538-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2020-06-25 | — | — | US | claimed |
| CN-110582564-A | derivation of liver organoids from human pluripotent stem cells | 新加坡科技研究局 | 2019-12-17 | — | — | CN | claimed |
| EP-3350313-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | Agency For Science, Technology And Research (A*star) (SG) | 2018-07-25 | — | — | EP | claimed |
| WO-2017048193-A1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2017-03-23 | — | — | WO | claimed |
| WO-2005079419-A2 | METHODS OF TREATING IMMUNOPATHOLOGICAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-01 | — | — | WO | claimed |
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4281051-A1 | VESICLES AND USES THEREOF | Exocure Sweden AB (SE) | 2023-11-29 | — | — | EP | disclosed |
| WO-2023084039-A1 | ASSESSMENT OF GR CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION | INNOSIGN B.V. (NL) | 2023-05-19 | — | — | WO | disclosed |
| EP-4176879-A1 | COMBINATION THERAPY FOR PROSTATE CANCER | JANSSEN Pharmaceutica NV (BE) | 2023-05-10 | — | — | EP | disclosed |
| EP-4176878-A1 | COMBINATION THERAPY FOR PROSTATE CANCER | JANSSEN Pharmaceutica NV (BE) | 2023-05-10 | — | — | EP | disclosed |
| US-20230119226-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2010068311-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| CN-101721349-A | Injectable in-situ crosslinking aquogel and preparation method and application thereof | CHANGZHOU BIOREGEN BIOMEDICAL | 2010-06-09 | — | — | CN | disclosed |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | AMIRA PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| EP-1613273-A4 | RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF | MEDIMMUNE INC (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1613273-A2 | RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF | MedImmune, Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004091510-A2 | RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF | MEDIMMUNE, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-4966770-A | Prednisone microencapsulated granules | HIMEDICS, INC. (US) | 1990-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | NR3C1 3/4885HSD17B10 2855/4885HIF1A 4422/4885 |
| US-20110034558-A1 | DP2 Antagonist and Uses Thereof | PTGER2, PTGES2, PTGDR2 | NR3C1 460/4885HSD17B10 1972/4885HIF1A 1136/4885 |
| US-20090291981-A1 | 5-Lipoxygenase-Activating Protein Inhibitor | ALOX5, LTA4H, ALOX5AP | NR3C1 1962/4885HSD17B10 652/4885HIF1A 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.